≡

Eukaryotic Biglycan (BGN)

DSPG1; PG-S1; PGI; SLRR1A; Biglycan Proteoglycan; Bone/cartilage proteoglycan I

  • Product No.EPJ226Hu61
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceEukaryotic expression
  • Host293F cell
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Predicted Molecular Massn/a
  • Accurate Molecular Massn/a(Analysis of differences refer to the manual)
  • Residues & TagsN-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder
  • Purity> 90%
  • Isoelectric Pointn/a
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • Downloadn/a
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$   US$   US$   US$   US$  
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in PBS or others.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Sci Rep.  Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysreCavia (Guinea pig )lation of biglycan Pubmed:27295191
Cell Death & Disease Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. pubmed:29022912
Diabetes & Vascular Disease Research Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve Pubmed: 30563371
博士论文 Die Rolle der extrazellulären Matrix in der degenerativen Aortenklappenerkrankung unter dem Einfluss von Diabetes
J Transl Med Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555
researchsquare Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic Efficacy 33966638
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ226Hu01 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
APJ226Hu03 Active Biglycan (BGN) Cell culture; Activity Assays.
RPJ226Hu03 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
EPJ226Hu61 Eukaryotic Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
RPJ226Hu02 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ226Hu01 Polyclonal Antibody to Biglycan (BGN) WB
PAJ226Hu02 Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC/IF
LAJ226Hu71 Biotin-Linked Polyclonal Antibody to Biglycan (BGN) WB
SEJ226Hu ELISA Kit for Biglycan (BGN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMJ226Hu Multiplex Assay Kit for Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.